NCT02729142

Brief Summary

The optimal management of calcium and phosphate metabolism regulation in chronic kidney disease (CKD) is important in preventing fracture risk and vascular calcification and thus morbidity and mortality, global and vascular. Kidney transplant in a CKD context, usually with a pre-existing underlying renal osteodystrophy, malnutrition, chronic inflammation, hypogonadism and immunosuppression protocols still often made up of high-dose corticosteroid therapy, are all theoretical factors of post-transplantation bone disease. For other solid organ transplants, even though there is generally no underlying renal osteodystrophy before the transplant, the proportion of osteoporotic patients at the time of transplant is substantial. The bone risk in the immediate post-transplant period is notable. Patients' follow-up is based on biological, radiological and histological tools. Bone densitometry (DXA) is used to measure bone mass. However, recent international recommendations do not consider DXA as a valid tool to assess bone health in CKD patients. Moreover, it is less informative than peripheral quantitative tomography resolution (HR-pQCT). This latest technique, available in Lyon and Saint-Etienne, is more precise, allowing a three-dimensional study of the trabecular microarchitecture and compartmental volumetric bone density (total, cortical, trabecular), while similar to DXA in terms of radiation (less than 5 μSv). The prevention of cardiovascular risk factors is also part of the daily care of patients with a regular cardiac monitoring (heart ultrasound) and vascular (blood pressure, Doppler of the supra-aortic trunks). TRANSOS study aims to evaluate in a prospective cohort (longitudinal follow-up of 6 months), the bone status in patients receiving solid organ transplantation in the University Hospitals of Lyon and Saint-Etienne, using DXA and HR-pQCT (at baseline and month 6), in combination with classical biological and cardiovascular monitoring. Transplantation is an important activity in these two hospitals and this protocol provides the same bone follow-up for all solid organ transplants, with a reliable, efficient, non-invasive and low-dose radiation tool. The primary objective of TRANSOS study is to evaluate changes in tibial cortical density between the baseline and the 6th month post-transplant measured by HR-pQCT.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
137

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jun 2016

Longer than P75 for not_applicable

Geographic Reach
1 country

3 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 25, 2016

Completed
12 days until next milestone

First Posted

Study publicly available on registry

April 6, 2016

Completed
2 months until next milestone

Study Start

First participant enrolled

June 7, 2016

Completed
4.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 8, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 8, 2020

Completed
Last Updated

August 22, 2025

Status Verified

November 1, 2020

Enrollment Period

4.3 years

First QC Date

March 25, 2016

Last Update Submit

August 20, 2025

Conditions

Keywords

HRpQCTtransplantbone microarchitecture

Outcome Measures

Primary Outcomes (1)

  • Tibial cortical density measured by HR-pQCT

    at 6 months

Secondary Outcomes (25)

  • trabecular bone area measured by HR-pQCT

    at 6 months

  • total bone area measured by HR-pQCT

    at 6 months

  • trabecular number measured by HR-pQCT

    at 6 months

  • trabecular thickness measured by HR-pQCT

    at 6 months

  • trabecular separation measured by HR-pQCT

    at 6 months

  • +20 more secondary outcomes

Study Arms (1)

Tibial cortical density evaluation

EXPERIMENTAL
Procedure: Tibial cortical density evaluation

Interventions

Bone evaluation in transplant patients will be performed by HR-pQCT at baseline (either within 6 months before surgery or within 15 days following surgery) and 6 months post-intervention in order to assess its evolution.

Tibial cortical density evaluation

Eligibility Criteria

Age10 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Patient over 10 year-old
  • Patient receiving a first solid organ transplant within involved hospitals (Lyon, Saint Etienne): kidney, heart, kidney-pancreas, lung
  • Informed consent signed by the patients or their parents (minors)

You may not qualify if:

  • No health cover
  • Ongoing pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Hôpital Femme Mère Enfant

Bron, France

Location

Hopital Edouard Herriot

Lyon, France

Location

CHU Saint Etienne

Saint-Etienne, France

Location

Related Publications (1)

  • De Mul A, Leclerc AS, Ginhoux T, Levi C, Confavreux C, Aurelle M, Portefaix A, Bacchetta J. Changes in bone density and microarchitecture in adolescents undergoing a first kidney transplantation: a prospective study. Eur J Pediatr. 2024 Dec;183(12):5303-5312. doi: 10.1007/s00431-024-05777-z. Epub 2024 Oct 9.

Study Officials

  • Charlene LEVI, Doctor

    Hospices Civils de Lyon

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 25, 2016

First Posted

April 6, 2016

Study Start

June 7, 2016

Primary Completion

October 8, 2020

Study Completion

October 8, 2020

Last Updated

August 22, 2025

Record last verified: 2020-11

Locations